Temozolomide

CAS 85622-93-1 19 current records 1 historicalSmall Molecule

Who holds supplier records for Temozolomide? 19 organisations hold a current record for Temozolomide: an active US FDA Type II Drug Master File or a CEP. A further 1 organisation has only historical (inactive) DMF filings. 8 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (8), China (3), Germany (1), Taiwan (1) and 5 other countries (5); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Temozolomide: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/temozolomide

Reading the evidence

  • 19 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 9 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (19)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Temozolomide. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Temozolomide sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (8)

Certificates of Suitability on the EDQM register for Temozolomide, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

HolderCountryCertificateIssuedEU GMP at holder's address
BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED HyderabadIN
CEP 2019-053 - Rev 01
Temozolomide
Mar 2026—
EXCELLA GMBH & CO. KG FeuchtDE
CEP 2018-246 - Rev 04
Temozolomide
Sept 2025Inspected Apr 2026
Germany
FORMOSA LABORATORIES, INC. TaoyuanTW
CEP 2017-245 - Rev 02
Temozolomide
Jul 2025Inspected May 2025
Poland
SHILPA PHARMA LIFESCIENCES LIMITED RaichurIN
CEP 2016-277 - Rev 01
Temozolomide
Jul 2025—
HETERO LABS LIMITED HyderabadIN
CEP 2017-270 - Rev 02
Temozolomide, Form-III
Feb 2025—
SHIVALIK RASAYAN LIMITED New DelhiIN
CEP 2021-394 - Rev 00
Temozolomide
Nov 2023—
WAVELENGTH ENTERPRISES LTD. Petah TikvaIL
CEP 2020-426 - Rev 01
Temozolomide
Sept 2023—
SUZHOU LIXIN PHARMACEUTICAL CO., LTD. SuzhouCN
R0-CEP 2020-359 - Rev 00
Temozolomide
Apr 2022—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (1)

Organisations whose Type II DMFs for Temozolomide are no longer active. These show a past filing, not current supply.

Show all 1 historical record

Overview

Temozolomide is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL810).

Chemical identity

IUPAC name
3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
Canonical SMILES
CN1C(=O)N2C=NC(=C2N=N1)C(=O)N
InChIKey
BPEGJWRSRHCHSN-UHFFFAOYSA-N
Synonyms
CCRG-81045, M-39831, M&B 39831, M&B-39831, Methazolastone, Mk-7365, NSC-362856, SCH 52365, SCH-52365, Temodal, Temodar, Temomedac

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Alkylating Drug
Mechanism of action
Alkylating Activity

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Temozolomide?

19 organisations hold an active US FDA Type II Drug Master File or a CEP for Temozolomide: EXCELLA GMBH AND CO KG (Germany), Formosa Laboratories, Inc. (Taiwan), Hetero Labs Limited (India), SHILPA PHARMA LIFESCIENCES LTD (India), WAVELENGTH ENTERPRISES LTD (Israel), Ampac Fine Chemicals (United States), BEIJING LUNARSUN PHARMACEUTICAL CO LTD and CHEMWERTH INC (France), and 11 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Temozolomide Drug Master Files are active?

EXCELLA GMBH AND CO KG (DMF 26032), Formosa Laboratories, Inc. (DMF 23158), Hetero Labs Limited (DMF 25344), SHILPA PHARMA LIFESCIENCES LTD (DMF 23479), WAVELENGTH ENTERPRISES LTD (DMF 19347), Ampac Fine Chemicals (DMF 28580), BEIJING LUNARSUN PHARMACEUTICAL CO LTD (DMF 24352) and CHEMWERTH INC (DMF 23547) and 8 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Temozolomide records mean?

1 organisation has only inactive Type II DMFs for Temozolomide. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Temozolomide have a European Certificate of Suitability?

Yes. 8 organisations hold a valid CEP for Temozolomide on the EDQM register, including BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED Hyderabad (IN), EXCELLA GMBH & CO. KG Feucht (DE), FORMOSA LABORATORIES, INC. Taoyuan (TW), SHILPA PHARMA LIFESCIENCES LIMITED Raichur (IN), HETERO LABS LIMITED Hyderabad (IN) and SHIVALIK RASAYAN LIMITED New Delhi (IN) and 2 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

How do I qualify a Temozolomide supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Temozolomide?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.